Latest News and Press Releases

Lead asset CT-01 on track for clinical trial application authorization in Q3 2023 Collaboration with Ono Pharmaceuticals in neurological diseases progressing according to planSolid cash position...

CT-01 targets 3 well suited proteins including NEK7 with poor prognosis in key liver cancerStrong preclinical data generated with CT-02 against NEK7CT-05 potential best-in-class profile in high...

WROCŁAW, Poland, March 07, 2023 (GLOBE NEWSWIRE) -- Captor Therapeutics S.A. (“Captor”) (WSE:CTX), a leader in the development of Targeted Protein Degradation (TPD)-based drugs, today announced its...

WROCŁAW, Poland, Nov. 25, 2022 (GLOBE NEWSWIRE) -- Captor Therapeutics S.A. (WSE:CTX), a biopharmaceutical company dedicated to the development of Targeted Protein Degradation (TPD)-based drugs for...

WROCŁAW, Poland, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Captor Therapeutics S.A. (WSE: CTX), a leader in the development of Targeted Protein Degradation (TPD)-based drugs, today announces a worldwide...

WROCŁAW, Poland, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Captor Therapeutics S.A. (WSE:CTX), a biopharmaceutical company dedicated to the development of Targeted Protein Degradation (TPD)-based drugs for...

WROCŁAW, Poland, May 05, 2022 (GLOBE NEWSWIRE) -- Captor Therapeutics S.A. (WSE:CTX), a biopharmaceutical company focused on the development of targeted protein degradation (TPD) drugs for cancer...

CT-01 compounds induce degradation of GSPT1, SALL4 and another as yet undisclosed neo-substrateThe unique degradation profile supports the strong competitive potential of the programCompelling...

WROCLAW, Poland, April 11, 2022 (GLOBE NEWSWIRE) -- Captor Therapeutics S.A. (WSE:CTX), a biopharmaceutical company focused on the development of targeted protein degradation (TPD) drugs for cancer...

Data confirm strong anticancer activity of two lead compounds in CT-01 programResults support advancement of CT-01 compounds towards IND expected in late 2022 WROCŁAW, Poland, Jan. 13, 2022 ...